High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy
NCT07926217, Phase 2, Recruiting, Sung-Han Kim
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy | ClinicalTrials.gov |
| NCT number | NCT07926217 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Phase 2 | ClinicalTrials.gov |
| Enrollment | 60 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Sung-Han Kim | ClinicalTrials.gov |
| Conditions | Hematologic Malignancy, Influenza | ClinicalTrials.gov |
| Interventions | High-dose inactivated influenza vaccine, Standard-dose inactivated influenza vaccine | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Seroconversion Rate at Day 28 After Influenza Vaccination | Day 28 (±7 days) after vaccination | Percentage of participants with seroconversion, measured by hemagglutination inhibition (HAI) assay and defined in the study protocol. Seroconversion is analyzed as seroconversion to at least one vaccine strain (each participant counted once) and separately for each vaccine strain. | ClinicalTrials.gov |
| Secondary | Geometric Mean Fold Rise of Hemagglutination Inhibition Titer | Day 28 (±7 days), Day 180 (±30 days), and Day 365 (±30 days) after vaccination | Geometric mean of the within-participant ratio of post-vaccination to baseline HAI titer, reported for each vaccine strain. | ClinicalTrials.gov |
| Secondary | Proportion of Participants With Hemagglutination Inhibition Titer of at Least 1:40 | Day 28 (±7 days), Day 180 (±30 days), and Day 365 (±30 days) after vaccination | Percentage of participants with an HAI titer of 1:40 or greater, reported for each vaccine strain. | ClinicalTrials.gov |
| Secondary | Frequency of Polyfunctional Influenza-Specific CD4-Positive and CD8-Positive T Cells | Baseline and Day 28 (±7 days) after vaccination | Percentage of CD4-positive and CD8-positive T cells co-expressing at least two of IFN-gamma, TNF-alpha, and IL-2 after stimulation with influenza hemagglutinin overlapping peptide pools, measured by intracellular cytokine staining | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 16
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 22904335 | BACKGROUND | PubMed |
| 26705931 | BACKGROUND | PubMed |
| 28263288 | BACKGROUND | PubMed |
| 33175132 | BACKGROUND | PubMed |
| 33461835 | BACKGROUND | PubMed |
| 33683337 | BACKGROUND | PubMed |
| 39219510 | BACKGROUND | PubMed |
| 39813653 | BACKGROUND | PubMed |
| 40032074 | BACKGROUND | PubMed |
| 40198276 | BACKGROUND | PubMed |
| 40562238 | BACKGROUND | PubMed |
| 40600710 | BACKGROUND | PubMed |
| 40879559 | BACKGROUND | PubMed |
| 40885198 | BACKGROUND | PubMed |
| 41160817 | BACKGROUND | PubMed |
| 41762115 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)